Immunocore Holdings (IMCR) opened 2026 with Q1 revenue of US$106.7 million and basic EPS of US$0.26, against a trailing twelve month revenue base of US$412.8 million and a basic EPS loss of US$0.55. Over recent quarters the company has reported revenue of US$84.1 million in Q4 2024, US$93.9 million in Q1 2025, US$98.0 million in Q2 2025, US$103.7 million in Q3 2025, US$104.5 million in Q4 2025 and US$106.7 million in Q1 2026. Over the same period, basic EPS has ranged from a loss of US$0.47 in Q4 2024 to a loss of US$0.20, near break-even, a loss of US$0.60 and then a return to positive territory at US$0.26. This sets up a quarter where margins and the path toward more consistent profitability are front of mind for investors.

See our full analysis for Immunocore Holdings.

With the headline numbers on the table, the next step is to set them against the prevailing narratives around Immunocore Holdings to see which stories the latest margins support and which ones start to look stretched.

US$12.9 million net income sets up a cleaner profit picture

• Net income excluding extra items swung to US$12.9 million in Q1 2026, compared with losses in four of the last five quarters, while trailing twelve month net income is still a loss of US$27.6 million on US$412.8 million of revenue.
• What stands out for the bullish narrative is that this positive quarter comes in a year where trailing twelve month losses have already narrowed from US$51.1 million in Q4 2024 to US$27.6 million in Q1 2026, even though analysts still describe the company as unprofitable.
  • Bulls argue that improving loss levels over the past five years at roughly a 35.5% annual rate support the idea that margins can move toward the 11.6% profit margin they reference for 3 years out.
  • The fact that Q1 produced US$12.9 million of net income, while the last twelve months still show a loss, gives bulls concrete recent data to point to, yet also reminds readers that consistency is not there yet.

Bulls point to this swing into profit as evidence the story is changing, but the trailing loss keeps the debate alive. That is exactly what the detailed bullish case tries to unpack in more depth 🐂 Immunocore Holdings Bull Case.

Revenue at US$412.8 million meets mixed profit trend

• On a trailing twelve month basis, revenue sits at US$412.8 million versus US$310.2 million in the period ending Q4 2024, while trailing EPS for Q1 2026 is a loss of US$0.55 compared with a loss of US$1.02 at Q4 2024.
• Bears focus on the fact that, despite this revenue base and narrowing EPS loss, the company is still described as unprofitable and expected to remain so for at least the next 3 years.
  • Critics highlight that even with revenue forecast at about 17.7% per year and trailing losses shrinking, analysts still do not expect profitability within 3 years, which fits the cautious view that higher R&D and operating spend can keep net income in the red.
  • The bearish narrative also flags heavy reliance on a single key product and ongoing pricing and competitive pressures, and the continued trailing loss of US$27.6 million gives that concern concrete backing despite the solid revenue line.

Skeptics see Q1 as a better quarter on its own, but the longer record of losses and reliance on one major product is central to their more cautious view on the story 🐻 Immunocore Holdings Bear Case.

P/S of 3.8x versus peers and DCF fair value gap

• At a current share price of US$30.62 and a trailing revenue base of US$412.8 million, the stock is cited as trading on a P/S of 3.8x compared with 13.7x for peers and 10.9x for the wider US biotechs industry, and analysis data also reference a DCF fair value of US$201.53.
• Consensus narrative mentions that the stock is trading about 84.8% below this DCF fair value and below the analyst price target of US$63.80, yet the same data set also states that the company is not expected to be profitable within 3 years. This sets up a clear tension between valuation signals and the profit timeline.
  • Supporters of the consensus view point to the lower P/S multiple alongside revenue forecast around 15.7% to 17.7% per year as reasons why some investors might see room for re rating if revenue trends hold.
  • On the other hand, the expectation of continued losses and the need for margin improvement from roughly a 5.7% loss toward industry like levels are the reasons many will still treat the P/S discount and DCF fair value gap with caution.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Immunocore Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment divided between improving margins and ongoing losses, this is a good moment to move quickly, examine the figures yourself, and weigh both sides. To see what the data suggests about the balance of opportunities and concerns, take a look at the 3 key rewards and 1 important warning sign

See What Else Is Out There

Immunocore Holdings still reports trailing twelve month losses, faces questions about consistent profitability, and carries concentration risk around a single key product.

If you want ideas where the focus is on stronger financial profiles and potentially steadier earnings paths, check out the solid balance sheet and fundamentals stocks screener (44 results) to compare alternatives side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.